Hyperway Pharmaceutical has raised over RMB 200 million (USD 28 million) in Series B funding led by Huagai Capital, supporting clinical development of its novel small-molecule pipeline. The China-based company's lead assets include Nav1.8 inhibitor HBW-004285 for acute postoperative pain, currently in Phase II and with a US filing planned, as well as fourth-generation BTK inhibitor HBW-3220, showing superior efficacy versus pirtobrutinib in chronic lymphocytic leukaemia (CLL) patients resistant to irreversible BTK inhibitors. The company's KRAS programme features KRAS G12D inhibitor HBW-012336, addressing oral bioavailability challenges, as well as pan-KRAS inhibitor HBW-012462, targeting both active and inactive states, with investigational new drug (IND) application already submitted.

The financing accelerates the clinical advancement of 10 differentiated programmes across oncology, pain management and central nervous system (CNS) disorders, leveraging blood-brain barrier (BBB) penetration platform technology. Investors highlighted pipeline quality and execution efficiency, with 11 pre-clinical candidate nominations and 7 clinical trial approvals achieved within 6 years of operation, demonstrating potential for best-in-class therapeutics addressing global unmet medical needs.

According to PharmCube's MedAlpha® database, this is the eighth funding round carried out by Hyperway, with USD 54 million raised reported so far. Click here to request a free trial for MedAlpha®.